Industry News

Our news page will keep you informed of press releases and news articles on rapid and alternative microbiological method technologies and updates from technology suppliers.

Please click here to submit your news.

Chembio’s DPP® HIV-Syphilis Assay Receives CE Mark for Simultaneous Point-of-Care Detection of HIV and Syphilis

Chembio Diagnostics, Inc. (CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, announced that it has received a CE mark for its DPP® HIV-Syphilis combination assay. The Chembio DPP® HIV-Syphilis Assay is now cleared to be marketed and sold within the member states of the European Union and the Caribbean region, except for Puerto Rico.

The Chembio DPP® HIV-Syphilis Assay is a single-use, rapid screening test for the detection of antibodies to HIV types 1 and 2 and syphilis Treponema pallidum using fingerstick whole blood, venous whole blood, serum, or plasma. The test requires a small 10 µl blood sample, is highly sensitive and specific, provides results in as little as 15 minutes, has a built-in procedural control, can be stored at room temperature, and has up to a 24-month shelf life.

John Sperzel, Chembio's Chief Executive Officer, commented, "We are pleased to receive a CE mark for our DPP® HIV-Syphilis Assay, which allows us to market and sell the test in Europe and the Caribbean region, except for Puerto Rico. We believe the DPP® HIV-Syphilis Assay can play a role in the global initiative to reduce transmission of HIV and syphilis to unborn children, as well as to screen certain populations to address growing HIV and syphilis co-infection rates."

Co-infection rates of HIV and syphilis are on the rise and, according to the Centers for Disease Control and Prevention, there is an estimated two-to-five-fold increased risk of contracting HIV if exposed to that infection when syphilis is present. Further, an estimated two million pregnancies annually are affected by mother-to-child-transmission of HIV and/or syphilis, resulting in high rates of stillbirth, spontaneous abortion, low birth weight and perinatal death. Congenital syphilis is a preventable disease, which could be significantly reduced through effective prenatal screening, and treatment of infected pregnant women.

"We intend to leverage our patented DPP® platform to deliver diagnostic tests that are most needed in each corner of the world. In the U.S., our goal is to bring our DPP® HIV-Syphilis Assay to market as quickly as possible, as there currently are no other such combination tests available in the U.S. market. We plan to complete a U.S. clinical trial for our DPP® HIV-Syphilis Assay and file for U.S. regulatory approval in early 2017.  In addition to our receipt of a CE mark for the DPP® HIV-Syphilis Assay, we have previous regulatory approvals in Mexico and Brazil, and we are working to obtain approvals in certain Southeast Asia countries, following our recent acquisition of Malaysia-based RVR Diagnostics,” added Sperzel.

Post a Comment

Previous Post Next Post

Contact Form